Yimingonco-B (01541): The first patient in the Phase II randomized placebo-controlled trial of IMM0306 for the treatment of SLE has been dosed.

Zhtng Cijng APP Xn, Ymng'ng K-B (01541) fb gnggo, IMM0306 zhlio xtng xng hngbng lng lu (SLE) de II q suj j nwi j du shyn shnl wnchng shu l hnzh jyo. Yq jing zhom yu 90 l hnzh, bng n 1:1:1 de bl suj fnpi zh sn g zhlio z, fnbi jishu IMM0306 (jling wi 1.2 mg/kg j 1.6 mg/kg) hu nwi j de zhlio.